The World's Oldest Probiotic: Perspectives for Health Claims

Probiotics and Health Claims

Volumn , Issue , 2010, Pages 17-36

  Sako, Tomoyuki ^a  

^a Yakult Europe BV   (Netherlands)

Author keywords

Actual benefits, in terms of microbiota composition from drinking Yakult; Dr Minoru Shirota, isolation of acid and bile tolerant Lactobacillus strain from 300 strains of lactic acid bacteria; Immune modulation activity natural killer (NK) cell activity, good indicator of general strength of human immune response; LcS effect on constipation and bowel discomfort investigations in clinical studies; Microorganisms, as OK 432 and BCG as anticancer biological response modifiers; Probiotic definition and basic ideas of Shirota and Metchnikoff; Species L. casei, the Shirota strain length of time, that most of L. casei paracasei group had classified as L. casei; World's oldest probiotic, health claims discovery of health promoting microbes; Yakult consumption effect on intestinal microbiota of humans; Yakult, a fermented food containing live cells of L. casei, lactic acid bacterial species

Indexed keywords

EID: 84885995978     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444329384.ch2     Document Type: Chapter

References (81)

1. Andoniou CE., van Dommelen SL., Voigt V et al. (2005) Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 6:1011-1019.
2. Aritaki S., Ishikawa S (1962) Application of a fermented milk drink containing Lactobacillus acidophilus in the field of paediatrics [in Japanese]. Jpn J Paediatrics 66:125-130.
3. Asahara T., Takahashi M., Nomoto K., et al. (2003) Assessment of safety of Lactobacillus strains based on resistance to host innate defence mechanisms. Clin Diagn Lab Immunol 10:169-173.
4. Asano M., Karasawa E., Takayama T (1987) Antitumor activity of Lactobacillus casei (LC 9018) against experimental mouse bladder tumor (MBT-2). J Urol 136:719-721.
5. Aso Y., Akazan H (1992) Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group. Urol Int 49:125-129.
6. Aso Y., Akaza H., Kotake T et al. (1995) Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol 27:104-109.
7. Candy DC., Densham L., Lamont LS et al. (2001) Effect of administration of Lactobacillus casei Shirota on sodium balance in an infant with short bowel syndrome. J Pediatr Gastroenterol Nutr 32:506-508.
8. Cats A., Kuipers EJ., Bosschaer MAR., Pot RGJ., Vandenbroucke-Grasus CMJE., Kusters JG (2003) Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 17:429-435.
9. De Preter V., Geboes K., Verbrugghe K et al. (2004) The in vivo use of the stable isotyope-labelled biomarkers lactose-[15N]ureide and [2H4]tyrosine to assess the effects of pro-and prebiotics on the intestinal flora of healthy human volunteers. Br J Nutr 92:439-446.
10. De Preter V., Vanhoutte T., Huys G et al. (2007) Effects of Lactobacillus casei Shirota., Bifidobacterium breve., and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol 292:G358-G368.
11. De Preter V., Raemen M., Cloetens L., Houben E., Rutgeerts P., Verbeke K (2008) Effect of dietary intervention with different pre-and probiotics on intestinal bacterial enzyme activities. Eur J Clin Nutr 62:225-231.
12. de Waard R., Garssen J., Bokken GCAM., Vos JG (2002) Antagonistic activity of Lactobacillus casei strain Shirota against gastrointestinal Listeria monocytogenes infection in rats. Int J Food Microbiol 73:93-100.
13. de Waard R., Claassen E., Bokken GCAM., Buiting B., Garssen J., Vos JG (2003) Enhanced immunological memory responses to Listeria monocytogenes in rodents., as measured by delayed-type hypersensitivity (DTH)., adoptive transfer of DTH., and protective immunity., following Lactobacillus casei Shirota ingestion. Clin Diagn Lab Immunol 10:59-65.
14. Gasbarrini A., Lauritano EC., Garcovich M., Sparano L., Gasbarrini G (2008) New insights into the pathophysiology of IBS: intestinal microflora., gas production and gut motility. Eur Rev Med Pharmacol Sci 12(Suppl 1):111-117.
15. Goehler LE., Lyte M., Gaykema RP (2007) Infection-induced viscerosensory signals from the gut enhance anxiety: implications for psychoneuroimmunology. Brain Behav Immun 21:721-726.
16. Haas C., Ryffel B., Le Hir M (1997) IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol 158:5484-5491.
17. Hayatsu H., Hayatsu T (1993) Suppressing effect of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. Cancer Lett 73:173-179.
18. Hernandez-Mendoza A., Guzman-de-Peña D., Garcia HS (2009) Key role of teichoic acids on aflatoxin B1 binding by probiotic bacteria. J Appl Microbiol 107:395-403.
19. Hori T., Kiyoshima J., Shida K., Yasui H (2002) Augmentation of cellular immunity and reduction of influenza virus titer in aged mice fed Lactobacillus casei strain Shirota. Clin Diagn Lab Immunol 9:105-108.
20. Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence. Lancet 356:1795-1799.
21. Ishikawa H., Akedo I., Otani T et al. (2005) Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 116:762-767.
22. Ivory K., Chambers SJ., Prieto C., Pin E., Arquez JL., Nicoletti C (2008) Oral delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Clin Exp Allergy 38:1282-1289.
23. Jacalne AV., Jacalne RR., Hirano H., Suetomi T., Villahermosa CG., Castaneda I (1990) In vivo studies on the use of Lactobacillus casei (Yakult strain) as biological agent for the prevention and control of diarrhea. Acta Medica Philippina 26:116-122.
24. Kalinski P., Mailliard RB., Giermasz A et al. (2005) Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther 5:1303-1315.
25. Kanamori Y., Hashizume K., Sugiyama M., Moritomi M., Yuki N., Tanaka R (2002) A novel synbiotic therapy dramatically improved the intestinal function of a pediatric patient with laryngotracheo-esophageal cleft (LTEC) in the intensive care unit. Clin Nutr 21:527-530.
26. Kanamori Y., Sugiyama M., Hashizume K., Yuki N., Morotomi M., Tanaka R (2004) Experience of long-term synbiotic therapy in seven short bowel patients with refractory enterocolitis. J Pediatr Surg 39:1686-1692.
27. Kato I., Endo-Tanaka K., Yokokura T (1998) Suppressive effects of the oral administration of Lactobacillus casei on type-II collagen-induced arthritis in DBA/1 mice. Life Sci 63:635-644.
28. Kawamura T., Ohnuki K., Ichida F (1981) Clinical study of BLG-01 including Lactobacillus casei on irregular movement and abdominal discomfort [in Japanese]. Pharmacol Ther 9:4361-4370.
29. Kikuchi K (1962) Fluctuation of number of coli bacilli and lactobacilli in human stool by peroral administration of Yakult [in Japanese]. Teishin Medical J 14:65-66.
30. Koebnick C., Wagner I., Leitzmann P., Stern U., Zunft HF (2003) Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 17:39-48.
31. Kotani S., Chiba H., Takeuchi K., Uchida K., Shimizu T., Sonoguchi T (1961) A study of the influence of cow's milk fermented by some kind of 'Family Lactobacillaceae' upon human body [in Japanese]. Jpn J Public Hygiene 8:29-53.
32. Maher KJ., Klimas NG., Fletcher., MA (2005) Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol 142:505-511.
33. Matsumoto K., Takada T., Shimizu K et al. (2006) The effects of a probiotic milk product containing Lactobacillus casei strain Shirota on the defecation frequency and the intestinal microflora of sub-optimal health state volunteers: a randomized placebo-controlled cross-over study. Biosci Microflora 25:39-48.
34. Matsumoto S., Watanabe N., Imaoka A., Okabe Y (2001) Preventive effects of Bifidobacterium-and Lactobacillus-fermented milk on the development of inflammatory bowel disease in senescenceaccelerated mouse P1/Yit strain mice. Digestion 64:92-99.
35. Matsumoto S., Hara T., Hori T et al. (2005) Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 140:417-426.
36. Matsumoto S., Hara T., Nagaoka M et al. (2008) A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitisassociated cancer. Immunology 128:e170-e180.
37. Matsuzaki T., Yokokura T (1989) Antitumor effect of oral administration of Lactobacillus casei in newborn mice [in Japanese]. Igaku no Ayumi 150:745-746.
38. Matsuzaki T., Nagata Y., Kado S et al. (1997a) Prevention of onset in an insulin-dependent diabetes mellitus model., NOD mice., by oral feeding of Lactobacillus casei. APMIS 105:643-649.
39. Matsuzaki T., Yamazaki R., Hashimoto S., Yokokura T (1997b) Antidiabetic effects of an oral administration of Lactobacillus casei in a non-insulin-dependent diabetes mellitus (NIDDM) model using KK-Ay mice. Endocrine J 44:357-365.
40. Matsuzaki T., Nagata Y., Kado S., Uchida K., Hashimoto S., Yokokura T (1997c) Effect of oral administration of Lactobacillus casei on alloxan-induced diabetes in mice. APMIS 105:637-642.
41. Matsuzaki T., Yamazaki R., Hashimoto S., Yokokura T (1998) The effect of oral feeding of Lactobacillus casei strain Shirota on immunoglobulin E production in mice. J Dairy Sci 81:48-53.
42. Matsuzaki T., Saito M., Usuku K., Nose H., Izumi S., Arimura K (2005) A prospective uncontrolled trial of fermented milk drink containing Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Neurol Sci 237:75-81.
43. Mihaylova I., DeRuyter M., Rummens JL., Bosmans E., Maes M (2007) Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuroendocrinol Lett 28:477-483.
44. Mike A., Nagaoka N., Tagami Y et al. (1999) Prevention of B220+ T cell expansion and prolongation of lifespan induced by Lactobacillus casei MRL/lpr mice. Clin Exp Immunol 117:368-375.
45. Morimoto K., Takeshita T., Nanno M., Tokudome S., Nakayama K (2005) Modulation of natural killer cell activity by supplementation of fermented milk containing Lactobacillus casei in habitual smokers. Prev Med 40:589-594.
46. Morita M (1973) Clinical use of a high-concentration Lactobacillus casei preparation [in Japanese]. J New Remed Clin 22:1351-1353.
47. Morotomi M., Mutai M (1986) In vitro binding of potent mutagenic pyrolyzates to intestinal bacteria. J Natl Cancer Inst 77:195-201.
48. Naito S., Koga H., Yamaguchi A et al. (2008) Prevention of recurrence with epirubicin and Lactobacillus casei after transurethral resection of bladder cancer. J Urol 179:485-490.
49. Numata K (1973) Clinical effect of a high concentrate lactobacilli preparation on chronic constipation [in Japanese]. Clinical Report 7:1856-1857.
50. Ogawa M., Shimizu K., Nomoto K et al. (2001) Protective effect of Lactobacillus casei strain Shirota on Shiga toxin-producing Escherichia coli 0157:H7 infection in infant rabbits. Infect Immun 69:1101-1108.
51. Ogawa T., Hirai R., Nakakuni H et al. (1974) Clinical experience with the use of the high-concentration lactic acid bacteria preparation LP-201 to treat habitual constipation: double-blinded placebo-controlled crossover study [in Japanese]. Clinical Report 8:1085-1092.
52. Ohashi Y., Nakai S., Tsukamoto T et al. (2002) Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int 68:273-280.
53. Ohta Z (1972) Clinical treatment to bowel discomfort of SMON patients with high-concentration Lactobacillus preparation [in Japanese]. Nihon Iji Shinpo No. 2514:25-31.
54. Ou G., Hedberg M., Hörstedt P et al. (2009) Proximal small intestinal microbiota and identification of rodshaped bacteria associated with childhood celiac disease. Am J Gastroenterol 104:3058-3067.
55. Paubert-Braquet M., Gan X-H., Gaudey C et al. (1995) Enhancement of host resistance against Salmonella typhimurium in mice fed a diet supplemented with yogurt or milks fermented with various Lactobacillus casei Shirota. Int J Immunotherapy 11:153-161.
56. Rao AV., Bested AC., Beaulne TM et al. (2009) A randomized double-blind placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathogens 1:6.
57. Sawamura A., Yamaguchi Y., Tohge T et al. (1994) Enhancement of immuno-activities by oral administration of Lactobacillus casei in colorectal cancer patients [in Japanese]. Biotherapy 8:1567-1572.
58. Sgouras D., Maragkoudakis P., Petraki K et al. (2004) In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 70:518-526.
59. Shida K., Takahashi R., Iwadate E et al. (2002) Lactobacillus casei strain Shirota suppressed serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. Clin Exp Allergy., 32:563-570.
60. Shida K., Suzuki T., Kiyoshima-Shibata J., Shimada S., Nanno M (2006a) Essential roles of monocytes in stimulating human peripheral blood mononuclear cells with Lactobacillus casei to produce cytokines and augment natural killer cell activity. Clin Vaccine Immunol 13:997-1003.
61. Shida K., Kiyoshima-Shibata J., Nagaoka M., Watanabe K., Nanno M (2006b) Induction of interleukin-12 by Lactobacillus strains having a rigid cell wall resistant to intracellular digestion. J Dairy Sci 89:3306-3317.
62. Shimizu K., Ogura H., Goto M et al. (2009) Synbiotics decrease the incidence of septic complications in patients with severe SIRS: a preliminary report. Dig Dis Sci 54:1071-1078.
63. Shimizu S., Shibamoto G (1964) Clinical observation of the effect of a strain of acidophilic lactic acid bacteria (Yakult strain) on the intestinal gas production [in Japanese]. Proc Tokyo Medical College 21:1-5.
64. Shirota M., Aso K., Iwabuchi A (1966) Study on the intestinal microflora: effect of the administration of Lactobacillus acidophilus strain Shirota on the composition of the intestinal microflora of healthy children [in Japanese]. Proc Jpn Soc Microbiol 21:274-283.
65. Spanhaak S., Havenaar R., Schaafsma G (1998) The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in human. Eur J Clin Nutr 52:899-907.
66. Strober W., Fuss I., Mannon P (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117:514-521.
67. Sugawara G., Nagino M., Nishio H et al. (2006) Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 244:706-14.
68. Sugita T., Togawa M (1994) Efficacy of Lactobacillus preparation Biolactis powder in children with rotavirus enteritis [in Japanese]. Jpn J Pediatr 47:2755-2762.
69. Takagi A., Matsuzaki T., Sato M., Nomoto K., Morotomi M., Yokokura T (1999) Inhibitory effect of oral administration of Lactobacillus casei on 3-methylcholanthrene-induced carcinogenesis in mice. Med Microbiol Immunol 188:111-116.
70. Takagi A., Matsuzaki T., Sato M., Nomoto K., Morotomi M., Yokokura T (2001) Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis 22:599-605.
71. Takeda K., Okumura K (2007) Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the human NK-cell activity. J Nutr 137:791S-793S.
72. Takeda K., Suzuki T., Shimada S-I., Shida K., Nanno M., Okumura K (2006) Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota. Clin Exp Immunol 146:109-115.
73. Tanaka R., Ohwaki M (1994) Effect of consumption of fermented milk drink containing Lactobacillus casei strain Shirota on the intestinal microflora and its metabolic activity [in Japanese]. Proc Int Flora Symposium 12:85-104.
74. Tohyama K., Kobayashi Y., Kan T., Yazawa K., Terashima T., Mutai M (1981) Effect of Lactobacillus on urinary indicant excretion in gnotobiotic rats and in man. Microbiol Immunol 25:101-112.
75. Tomita K., Akaza H., Nomoto K et al. (1994) Influence of Lactobacillus casei on rat bladder carcinogenesis [in Japanese]. Nippon Hinyokika Gakkai Zasshi 85:655-663.
76. Turnbaugh PJ., Ley RE., Mahowald MA., Magrini V., Mardis ER., Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027-1031.
77. Wu S., Rhee K-J., Albesiano E et al. (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016-1022.
78. Yasuda E., Serata M., Sako T (2008) Suppressive effect on activation of macrophages by Lactobacillus casei strain Shirota genes determining the synthesis of cell wall-associated polysaccharides. Appl Environ Microbiol 74:4746-4755.
79. Yasui H., Kiyoshima J., Hori T (2004) Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota. Clin Diagn Lab Immunol 11:675-679.
80. Yokokura T., Kato I., Mutai M (1981) Antitumor effect of Lactobacillus casei (LC 9018) [in Japanese]. In: Mitsuoka T (ed.) Intestinal Flora and Tumor Development. Tokyo: Gakkai Shuppan Center., pp. 125-137.
81. Yuki N., Watanabe K., Mike A et al. (1999) Survival of a probiotic., Lactobacillus casei strain Shirota., in the gastrointestinal tract: selective isolation from faeces and identification using monoclonal antibodies. Int J Food Microbiol 48:51-57.